Arcellx

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.

Arcellx (ACLX) Down on Hold for Lead Program CART-ddBCMA

Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its investigational new drug CART-ddBCMA for relapsed or refractory multiple myeloma was put on hold by the US Food and Drug Administration (FDA) following a patient's death. The analysts said they expected the negative regulatory update from Arcellx on Monday night to weigh on the stock, which closed down 7.2% at US$33.23 on Tuesday.

Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of $2.52. This compares to loss of $1.56 per share a year ago.

Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates

REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023.

Arcellx Provides First Quarter Financial Results

Chipotle

Harrow Health Inc

PROG Holdings

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.

5 Stocks With Recent Price Strength That Still Have Upside

Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy?

Arcellx, Inc. (ACLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know

Annovis Bio

Worthington Industries

ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.

Best Momentum Stocks to Buy for April 21st

Ryerson Hld

Siemens AG

WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.

New Strong Buy Stocks for April 21st

REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 1:00 p.m.

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know

Arcellx, Inc. (ACLX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy?

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates

-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma -- -- Enrolled and dosed patients in pivotal iMMagine-1 clinical program for patients with rrMM -- -- Initiated ACLX-002 for patients with AML/MDS -- REDWOOD CITY, Calif. , March 29, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C.

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the company's participation in the following investor conferences: Guggenheim Oncology Conference 2023Fireside chat on Thursday, February 9, 2023, at 11:20 a.m.

Arcellx to Participate in Upcoming Investor Conferences

Gilead Sciences

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--( BUSINESS WIRE )--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead.

Arcellx: The Gilead Deal Derisks And Proves Their Technology

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out. The post Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences appeared first on Investor's Business Daily.

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' Kite to co-develop and co-commercialize its late-stage product candidate, CART-dddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.  Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.

Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment

Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ).

Why Is Arcellx (ACLX) Stock Up 25% Today?

Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company.

Gilead to co-develop Arcellx's multiple myeloma drug

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--( BUSINESS WIRE )--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.

News for Arcellx Stock (ACLX)